{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:32:10Z","timestamp":1792675930175,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T00:00:00Z","timestamp":1286409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s11910-010-0151-1","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T06:00:55Z","timestamp":1286344855000},"page":"89-96","source":"Crossref","is-referenced-by-count":52,"title":["Treatment of Myasthenia Gravis"],"prefix":"10.1007","volume":"11","author":[{"given":"Vikas","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J.","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,7]]},"reference":[{"key":"151_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00605.x","volume":"183","author":"A Vincent","year":"2006","unstructured":"Vincent A: Immunology of disorders of neuromuscular transmission. Acta Neurol Scand Suppl 2006, 183:1\u20137.","journal-title":"Acta Neurol Scand Suppl"},{"key":"151_CR2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"\u2022 Leite MI, Jacob S, Viegas S, et al.: IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 2008, 131:1940\u20131952. This article indicates that even patients who do not have antibodies directed against the AChR or MuSK likely have low levels of serum antibodies that bind the AChR. Some of these seronegative patients still may have antibodies directed at other proteins.","journal-title":"Brain"},{"key":"151_CR3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ: Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 2006, 13:1006\u20131010.","journal-title":"J Clin Neurosci"},{"key":"151_CR4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B: A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998, 50:1778\u20131783.","journal-title":"Neurology"},{"key":"151_CR5","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","volume":"274","author":"FM Howard Jr","year":"1976","unstructured":"Howard FM Jr, Duane DD, Lambert EH, Daube JR: Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci 1976, 274:596\u2013607.","journal-title":"Ann N Y Acad Sci"},{"key":"151_CR6","doi-asserted-by":"crossref","unstructured":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group [no authors listed]. J Neurol Neurosurg Psychiatry 1993, 56:1157\u20131163.","DOI":"10.1136\/jnnp.56.11.1157"},{"key":"151_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11940-005-0001-7","volume":"7","author":"VC Juel","year":"2005","unstructured":"Juel VC, Massey JM: Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr Treat Options Neurol 2005, 7:3\u201314.","journal-title":"Curr Treat Options Neurol"},{"key":"151_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","volume":"150","author":"MB Bromberg","year":"1997","unstructured":"Bromberg MB, Wald JJ, Forshew DA, et al.: Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 1997, 150:59\u201362.","journal-title":"J Neurol Sci"},{"key":"151_CR9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","volume":"681","author":"RS Tindall","year":"1993","unstructured":"Tindall RS, Phillips JT, Rollins JA, et al.: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993, 681:539\u2013551.","journal-title":"Ann N Y Acad Sci"},{"key":"151_CR10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RS Tindall","year":"1987","unstructured":"Tindall RS, Rollins JA, Phillips JT, et al.: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987, 316:719\u2013724.","journal-title":"N Engl J Med"},{"key":"151_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000, 55:448\u2013450.","journal-title":"Neurology"},{"key":"151_CR12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85\u2013118.","journal-title":"Immunopharmacology"},{"key":"151_CR13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","volume":"56","author":"E Ciafaloni","year":"2001","unstructured":"Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB: Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001, 56:97\u201399.","journal-title":"Neurology"},{"key":"151_CR14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","volume":"998","author":"MN Meriggioli","year":"2003","unstructured":"Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003, 998:494\u2013499.","journal-title":"Ann N Y Acad Sci"},{"key":"151_CR15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"\u2022 Sanders DB, Hart IK, Mantegazza R, et al.: An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008, 71:400\u2013406. This study was a well-performed, randomized, placebo-controlled trial that showed no benefit of mycophenolate and prednisone compared with prednisone alone. The study likely did not have long enough periods of study.","journal-title":"Neurology"},{"key":"151_CR16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"Muscle Study Group","year":"2008","unstructured":"\u2022 Muscle Study Group: A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008, 71:394\u2013399. This study was a well-performed, randomized, placebo-controlled trial that showed no benefit of mycophenolate and prednisone compared with prednisone alone. The study likely did not have long enough periods of study.","journal-title":"Neurology"},{"key":"151_CR17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jneuroim.2007.12.008","volume":"195","author":"Y Furukawa","year":"2008","unstructured":"Furukawa Y, Yoshikawa H, Iwasa K, Yamada M: Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 2008, 195:108\u2013115.","journal-title":"J Neuroimmunol"},{"key":"151_CR18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079907X188080","volume":"23","author":"JM Ponseti","year":"2007","unstructured":"Ponseti JM, Gamez J, Azem J, et al.: Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. Curr Med Res Opin 2007, 23:1269\u20131278.","journal-title":"Curr Med Res Opin"},{"key":"151_CR19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","volume":"64","author":"JM Ponseti","year":"2005","unstructured":"Ponseti JM, Azem J, Fort JM, et al.: Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005, 64:1641\u20131643.","journal-title":"Neurology"},{"key":"151_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","volume":"53","author":"Y Nagane","year":"2005","unstructured":"Nagane Y, Utsugisawa K, Obara D, et al.: Efficacy of low-dose FK506 in the treatment of Myasthenia gravis\u2014a randomized pilot study. Eur Neurol 2005, 53:146\u2013150.","journal-title":"Eur Neurol"},{"key":"151_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ana.10449","volume":"53","author":"RA Lewis","year":"2003","unstructured":"Lewis RA, Lisak RP: \u201cRebooting\u201d the immune system with cyclophosphamide: taking risks for a \u201ccure\u201d? Ann Neurol 2003, 53:7\u20139.","journal-title":"Ann Neurol"},{"key":"151_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.cco.0000152974.65477.35","volume":"17","author":"DB Drachman","year":"2005","unstructured":"Drachman DB, Brodsky RA: High-dose therapy for autoimmune neurologic diseases. Curr Opin Oncol 2005, 17:83\u201388.","journal-title":"Curr Opin Oncol"},{"key":"151_CR23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","volume":"33","author":"PT Lin","year":"2006","unstructured":"Lin PT, Martin BA, Weinacker AB, So YT: High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 2006, 33:433\u2013435.","journal-title":"Muscle Nerve"},{"key":"151_CR24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG Feo De","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA: Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002, 26:31\u201336.","journal-title":"Muscle Nerve"},{"key":"151_CR25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","volume":"78","author":"WS Baek","year":"2007","unstructured":"Baek WS, Bashey A, Sheean GL: Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007, 78:771.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"151_CR26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","volume":"33","author":"B Hain","year":"2006","unstructured":"Hain B, Jordan K, Deschauer M, Zierz S: Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006, 33:575\u2013580.","journal-title":"Muscle Nerve"},{"key":"151_CR27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, et al.: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997, 41:789\u2013796.","journal-title":"Ann Neurol"},{"key":"151_CR28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J Ronager","year":"2001","unstructured":"Ronager J, Ravnborg M, Hermansen I, Vorstrup S: Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001, 25:967\u2013973.","journal-title":"Artif Organs"},{"key":"151_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mus.1221","volume":"25","author":"RS Bedlack","year":"2002","unstructured":"Bedlack RS, Sanders DB: Steroid treatment for myasthenia gravis: steroids have an important role. Muscle Nerve 2002, 25:117\u2013121.","journal-title":"Muscle Nerve"},{"key":"151_CR30","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","volume":"62","author":"P Gajdos","year":"2005","unstructured":"Gajdos P, Tranchant C, Clair B, et al.: Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005, 62:1689\u20131693.","journal-title":"Arch Neurol"},{"key":"151_CR31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"\u2022 Zinman L, Ng E, Bril V: IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007, 68:837\u2013841. The study is among the few controlled trials in MG. It demonstrates the efficacy of IVIG in the treatment of exacerbations of MG.","journal-title":"Neurology"},{"key":"151_CR32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","volume":"52","author":"AI Qureshi","year":"1999","unstructured":"Qureshi AI, Choudhry MA, Akbar MS, et al.: Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999, 52:629\u2013632.","journal-title":"Neurology"},{"key":"151_CR33","first-page":"939","volume":"12","author":"P Gajdos","year":"1983","unstructured":"Gajdos P, Simon N, de Rohan-Chabot P, et al.: [Long-term effects of plasma exchange in myasthenia. Results of a randomized study] [in French]. Presse Med 1983, 12:939\u2013942.","journal-title":"Presse Med"},{"key":"151_CR34","doi-asserted-by":"crossref","unstructured":"Gajdos P, Chevret S, Toyka K: Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev 2002, (4):CD002275.","DOI":"10.1002\/14651858.CD002275"},{"key":"151_CR35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GS Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7\u201315.","journal-title":"Neurology"},{"key":"151_CR36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1196\/annals.1405.014","volume":"1132","author":"J Newsom-Davis","year":"2008","unstructured":"\u2022 Newsom-Davis J, Cutter G, Wolfe GI, et al.: Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann N Y Acad Sci 2008, 1132:344\u2013347. The article describes the first randomized, single-blinded, controlled trial of thymectomy for patients with MG. The study is about two-thirds completed at the time of publication of this review.","journal-title":"Ann N Y Acad Sci"},{"key":"151_CR37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thorsurg.2008.09.013","volume":"19","author":"MJ Magee","year":"2009","unstructured":"Magee MJ, Mack MJ: Surgical approaches to the thymus in patients with myasthenia gravis. Thorac Surg Clin 2009, 19:83\u201389.","journal-title":"Thorac Surg Clin"},{"key":"151_CR38","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1378\/chest.128.5.3454","volume":"128","author":"A Manlulu","year":"2005","unstructured":"Manlulu A, Lee TW, Wan I, et al.: Video-assisted thoracic surgery thymectomy for nonthymomatous myasthenia gravis. Chest 2005, 128:3454\u20133460.","journal-title":"Chest"},{"key":"151_CR39","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","volume":"68","author":"M Benatar","year":"2007","unstructured":"Benatar M, Kaminski HJ: Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007, 68:2144\u20132149.","journal-title":"Neurology"},{"key":"151_CR40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","volume":"62","author":"N Sommer","year":"1997","unstructured":"Sommer N, Sigg B, Melms A, et al.: Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997, 62:156\u2013162.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"151_CR41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","volume":"89","author":"MJ Kupersmith","year":"2005","unstructured":"Kupersmith MJ, Ying G: Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol 2005, 89:1330\u20131334.","journal-title":"Br J Ophthalmol"},{"key":"151_CR42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E, et al.: Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 2003, 23:251\u2013255.","journal-title":"J Neuroophthalmol"},{"key":"151_CR43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","volume":"34","author":"A McGrogan","year":"2010","unstructured":"McGrogan A, Sneddon S, de Vries CS: The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010, 34:171\u2013183.","journal-title":"Neuroepidemiology"},{"key":"151_CR44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1055\/s-2004-829591","volume":"24","author":"PI Andrews","year":"2004","unstructured":"Andrews PI: Autoimmune myasthenia gravis in childhood. Semin Neurol 2004, 24:101\u2013110.","journal-title":"Semin Neurol"},{"key":"151_CR45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/WCO.0b013e32833c32af","volume":"23","author":"A Evoli","year":"2010","unstructured":"\u2022 Evoli A: Acquired myasthenia gravis in childhood. Curr Opin Neurol 2010, 23:536\u2013540. This is an outstanding review of the challenges faced in caring for pediatric patients with MG. The author is an outstanding clinical scientist with a wealth of clinical experience.","journal-title":"Curr Opin Neurol"},{"key":"151_CR46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S, et al.: Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365\u2013368.","journal-title":"Nat Med"},{"key":"151_CR47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"M Pasnoor","year":"2010","unstructured":"Pasnoor M, Wolfe GI, Nations S, et al.: Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010, 41:370\u2013374.","journal-title":"Muscle Nerve"},{"key":"151_CR48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","volume":"1132","author":"A Evoli","year":"2008","unstructured":"Evoli A, Bianchi MR, Riso R, et al.: Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008, 1132:76\u201383.","journal-title":"Ann N Y Acad Sci"},{"key":"151_CR49","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","volume":"23","author":"JT Guptill","year":"2010","unstructured":"Guptill JT, Sanders DB: Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010, 23:530\u2013535.","journal-title":"Curr Opin Neurol"},{"key":"151_CR50","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ: Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843\u20132854.","journal-title":"J Clin Invest"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-010-0151-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-010-0151-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T07:30:43Z","timestamp":1559719843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-010-0151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s11910-010-0151-1","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,7]]}}}